{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2015"],"condition":["Squamous Cell Carcinoma of Head and Neck","Carcinoma","Renal Cell Carcinoma (RCC) (Phase ll Only)","Glioblastoma","Carcinoma, Renal Cell","Ovarian Carcinoma-Enrollment Completed","Colorectal Cancer (CRC)-Enrollment Completed","Squamous Cell Carcinoma of the Head and Neck (SCCHN)","Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed"],"disease":["Squamous Cell Carcinoma Of The Head And Neck (scchn)","Squamous Cell Carcinoma Of Head And Neck","Renal Cell Carcinoma (rcc) (phase Ll Only)","Colorectal Cancer (crc)-enrollment Completed","Carcinoma","Glioblastoma (gbm) (phase Ll Only)-enrollment Completed","Glioblastoma","Carcinoma, Renal Cell","Ovarian Carcinoma-enrollment Completed"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2181728"],"location":["United States"],"study_start_month":["1"],"keyword":["Nivolumab","Opdivo"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors","description":"This is a study to determine the clinical benefit (how well the drug works), safety, and tolerability of combining varlilumab and nivolumab (also known as Opdivo , BMS-936558). Both drugs target the immune system and may act to promote anti-cancer effects.","dates":{"creation":"2015-01-15"},"accession":"2181728","cross_references":{"ClinicalTrials___gov":["NCT02335918"]}}